• Pending Media Exposure:  Jerusalem Post is expected to do a follow-up article to their article of October, 2002 "The Drug They Called Miraculous" upon the beginning of the three Israeli trials that have been approved by the Israeli Ministry of Health (Monitor for coverage at http://www.jpost.com  "Health Section")  
• Delay in the start of clinical trials that have been approved is due to capital constraints that should be alleviated by substantial investors, prompting the announcement of four trials to begin (one to restart at the Phase II stage in the US for HPV);and, three in Israel for HIV, CANCER and CACHEXIA (loss of weight during chemotherapy).
• Insider Financing: One Director and one Management Advisory Board member (both aware of all internal corporate developments) have invested $1.5 million (total) in ADVR at very favorable terms to ADVR 
• Unique history of drug strongly suggests that formal clinical trial results will reflect the previous experience of physicians and patients from the past-- efficacy and no side effects.
• Pending collaborative partnerships:  Company actively seeking a partner with a major Pharmaceutical to expedite research, clinical trials and eventual market approval. Market Caps of major Pharmas have suffered recently due to most firms in need of new promising drugs in their pipeline. 
• Drug's History of Use in the United States:--ADVR's drug is a successor to a drug that was used in the United States for 25 years (until 1962) for the treatment of influenza, herpes and hepatitis with no reported toxic side effects. Now, the drug has entered  Phase II clinical trials in the United States.  Patients using Reticulose in the past experienced excellent results (as reported by the patients AND  their treating physicians). The reformulated immunomodulator drug, Product R, could be a blockbuster drug for various conditions such as various cancers, HIV, genital warts, (HPV) genital herpes, West Nile virus,  lupus and rheumatoid arthritis. Patients have continued to obtain Reticulose through Canada under the FDA Individual Use Program (which requires certain documentation) and have contributed to a wealth of anecdotal evidence that attest to the drug's effectiveness and safety. The anecdotal evidence strongly indicate that clinical trials should go smoothly and rapidly. Product R, the second generation immunomodulator drug based on the science of Reticulose, is Advanced Viral Research's (ADVR) flagship drug that could be in three Phase I and/or Phase II clinical trials for Cancer, HIV and chemotherapy toxicity within weeks.
• U.S. Phase II trials for HPV:  Trials will be announced upon additional capital being secured (imminent). Patent filing for HPV references patient examples of daily topical treatments that resulted in no trace of HPV (determined by biopsy) after only 14 days. (Search US Patent and Trademark Office site http://www.uspto.gov) 
• Company's undervalued patent portfolio (issued and pending) include treatment of basal cell carcinoma, melanoma, anemia, suppressed immune systems (ie. during chemotherapy and severe burns), adenovirus, lupus, parvovirus, skin diseases (genital herpes, shingles, HPV, plantar warts etc.) and HIV (as an adjunct therapy with current FDA-approved therapies). Company holds patent for both the older drug ("Reticulose") and the improved drug ("Product R").
• Accelerated Drug Approval Potential:  ADVR will focus on and target IND (Investigational New Drug) applications to the U.S. FDA for therapeutic uses of Product R that may allow the Company to take advantage of FDA programs for orphan drugs and other accelerated tracks for drug approval  in order to attract significant investment from pharmaceutical partners.
• Huge Potential in Target Markets: Initial target markets are HPV ($200 million-$300 million annually), chemotherapy ($2.2 billion -$3 billion) and HIV (for patients experiencing toxic side effects with the protease inhibitor cocktails ($2.1billion-$3.3 billion).  Other markets will be addressed (patent portfolio gives the investor some insight into the potential markets) as the company's research progresses.
• Stock trading history  Reacts with dramatically higher volume on any positive news.  In Spring, 2000, ADVR appreciated from .25 to $1.75 in two weeks on weekly volume of up to 110 million shares.
• Stock is very liquid with tight Bid/Ask spreads and daily trading volumes recently ranging from 500,000 -2 million shares.

• stimulate the proinflammatory responses required to combat viral infections such as AIDS, herpes etc. 
• dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis and lupus
• interferes with the actual replication and growth of HPV in cell culture and the expression of a key protein implicated in the development of cervical cancer
• be an effective non-toxic drug for both systemic (by injection) and topical therapy of disseminated HPV infection in patients with AIDS (according to preliminary clinical results)   
• inhibit the production of both the CCR5 and CXCR4 chemokine receptors, the key cellular co-receptors for the human immunodeficiency virus (HIV) and,
• to mitigate the toxic side effects of other drugs, including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment of various cancers i.e. lymphatic lymphoma, melanoma, basal cell carcinoma etc. 

  ---

 

• Under Accumulation
• Poised on 200 Day Moving Average

Company Address

ADVR Corporate Office
200 Corporate Blvd. South
Yonkers, New York 10701

IR Contact

CHARLES MAYR
Phone: 877.777.6010
Email: MAYRCOMM@ATT.NET

WebSite: http://www.adviral.com/

Recent Press Releases

RagingBull Message board for Advr.ob

Yahoo Discussion Group For Advr.ob

Disclaimer/Disclosure

1) ADVR Advanced viral research corporation officers, directors, employees and or their affiliates and or
their contractors opinions aren't necessarily the opinion of PennyMarkets.com or any of its officers, directors and employees.

2) This ADVR profile from our findings has been written in a best effort by the author (Information should be independently verified!)

3) PennyMarkets.com. PennyMarkets.com is not a Registered Investment Advisor or a Broker/Dealer. All information provided must be understood as information provided and not investment advice. PennyMarkets.com. advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in any companies featured by PennyMarkets.com and Or anyone. All statements and expressions are the opinion of the companies featured or the writer(s)and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. The accuracy or completeness of the information on this website/email/post is only as reliable as the sources they were obtained from. PennyMarkets.com., its officers, directors, employees or any affiliated parties make no representation or warranty as to the accuracy of the information provided. All information concerning the companies featured herein should be verified independently with the featured company. Factual statements are made as of the date stated and are subject to change without notice. PennyMarkets.com. is not responsible for any claims made by any company. The receipt of this publication shall not create, under any circumstances, any implication that there has been no change in the affairs of the company profiled since the date of review. We do not provide any analysis of the featured company's financial position. Investments in all stocks are generally deemed to be highly speculative and do involve substantial risk, making it appropriate for readers to consult with professional investment advisors and to make independent investigations before acting on information published by PennyMarkets.com.. Investment in stocks could prove to be high-risk investments with the result of loss of part or total principal investment. Please review the S.E.C website at www.sec.gov/ before investing in anything. PennyMarkets.com., its affiliates,officers,directors,subsidiaries and agents (collectively, "PennyMarkets.com .") Will not receive any shares for profiling ADVR. Any and all compensation received from a company is publicly stated. All compensation if any can be found in the disclaimer section for each individual company. This compensation should be viewed as a potential conflict of interest. Furthermore, PennyMarkets.com. or its employees, associates, or affiliates and families may have financial positions in featured companies. PennyMarkets.com. and affiliates may or may not increase or decrease its ownership interest in any featured companies at any time before, during or after distribution of information. We may profit in the event the shares of the company featured by us increase in value. These positions may be liquidated from time to time even after we have made positive comments regarding the company. The receipt of this information constitutes your acceptance of these terms and conditions. If you have any questions about this disclaimer in whole or in part email us at Buchen@cmnwrld.com.com

4)SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS Except for historical
information contained herein, the statements on this website and and or newsletter are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results in the future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition and risk inherent in the companies operations. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ``anticipate,'' ``estimate,'' ``expect,'' ``project,'' ``intend,''``plan,'' ``believe,'' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance.

5) If you have any question(s) about this Disclaimer/Disclosure email us at Buchen@cmnwrld.com